NetraMark HoldingsAINMF -4.35%22 Altman Z-Score is 26.03 as of Jun. 27, 2026, which is 721% above its 10-year median of 3.17. GuruFocus rates AINMF with a GF Score™ of 22/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 662 Healthcare Providers & Services companies, NetraMark Holdings ranks better than 98.64% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 40.87 is strong.
NetraMark Holdings has a Altman Z-Score of 26.03, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for NetraMark Holdings's Altman Z-Score or its related term are showing as below:
AINMF'
s Altman Z-Score Range Over the Past 10 Years
Min: -272.4 Med: 3.17 Max: 173.53
Current: 40.87
During the past 6 years, NetraMark Holdings's highest Altman Z-Score was 173.53. The lowest was -272.40. And the median was 3.17.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
NetraMark Holdings Altman Z-Score Related Terms
NetraMark Holdings Altman Z-Score Historical Data
* Premium members only.
The historical data trend for NetraMark Holdings's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AINMF vs VEEV, BTSG, TEM: Altman Z-Score Comparison
For the Health Information Services subindustry, NetraMark Holdings's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NetraMark Holdings Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where NetraMark Holdings's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
NetraMark Holdings's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.8135
+
1.4
*
-11.5731
+
3.3
*
-1.6401
+
0.6
*
77.7051
+
1.0
*
0.0448
=
26.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
NetraMark Holdings (AINMF) has a Altman Z-Score of 26.03 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on NetraMark Holdings and its competitors. This is 721% above median its historical median of 3.17. According to the industry distribution chart, NetraMark Holdings ranks #9 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 1.4%.
Is NetraMark Holdings' Altman Z-Score too high?
NetraMark Holdings' current Altman Z-Score of 26.03 is 721% above median its 10-year median of 3.17. The Healthcare Providers & Services industry median Altman Z-Score is 2.36. NetraMark Holdings' value of 26.03 is 1003% above this industry median. Based on the distribution chart, NetraMark Holdings ranks #9 out of 662 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NetraMark Holdings has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NetraMark Holdings' Altman Z-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NetraMark Holdings ranks #9 out of 662 companies for Altman Z-Score. This places NetraMark Holdings in the top 1% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.36. NetraMark Holdings' value of 26.03 is 1003% above this benchmark. While the company's 10-year median is 3.17 vs. the industry median of 2.36, NetraMark Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.36, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NetraMark Holdings's current Altman Z-Score of 26.03 is 1003% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on NetraMark Holdings and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NetraMark Holdings's current Altman Z-Score is 26.03, which is 721% above median its own 10-year median of 3.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NetraMark Holdings stock overvalued right now?
Based on GuruFocus' analysis, NetraMark Holdings (AINMF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $0.42 — trading 100.2% above its estimated fair value. The current Altman Z-Score is 26.03, which is 721% above median its 10-year median of 3.17 and 1003% above the Healthcare Providers & Services industry median of 2.36. NetraMark Holdings' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For NetraMark Holdings (AINMF), the current Altman Z-Score is 26.03 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NetraMark Holdings (AINMF) Overvalued in 2026?
Based on GuruFocus' analysis, NetraMark Holdings stock appears to be overvalued.
The current stock price of $0.42 is trading 100.2% above its estimated GF Value™ of $0.21.
GuruFocus considers NetraMark Holdings to be Significantly Overvalued.
Key valuation signals for AINMF:
Altman Z-Score: 26.03 (721% above median its 10-year median of 3.17)
GF Value™: $0.21 vs. price of $0.42 (100.2% above fair value)
Industry Position: 1003% above the Healthcare Providers & Services median (#9 of 662)
No single metric tells the full story. See the AINMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NetraMark Holdings Inc provides AI-powered insights and software solutions to optimize clinical trial design and outcomes for pharmaceutical sponsors. The company offers AI solutions to trial sponsors, CROs, and biotechnology companies across the globe. It earns revenue from its proprietary NetraAI platform, an advanced machine learning system purpose-built to analyze complex clinical trial data and identify meaningful patient subpopulations.
22GF Score
Get the complete analysis for AINMF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AINMF has been successfully added to your 
